Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Biosimilar Education Campaign Will Need To Be Targeted

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.


Related Content

How US Can Learn From Biosimilar Implementation In EU
A New Year Filled With Debate Over Drug Pricing, PwC Predicts
Australia Targets Patients, Doctors In Biosimilar Awareness Campaign
Biosimilar Statistical Guidance Will Stress Flexibility, Woodcock Says
Biosimilar Tracking Still Possible With Shared Medicare Codes, Woodcock Suggests
Biosimilar User Fee Negotiations Won't Start Until 2016
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst